Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by EntryPoint Capital LLC

EntryPoint Capital LLC raised its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 214.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 29,144 shares of the company’s stock after acquiring an additional 19,862 shares during the quarter. Castle Biosciences makes up 0.3% of EntryPoint Capital LLC’s investment portfolio, making the stock its 14th biggest holding. EntryPoint Capital LLC owned about 0.10% of Castle Biosciences worth $777,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Algert Global LLC increased its position in Castle Biosciences by 0.4% during the 3rd quarter. Algert Global LLC now owns 134,321 shares of the company’s stock worth $3,831,000 after purchasing an additional 599 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Castle Biosciences by 11.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock valued at $158,000 after buying an additional 604 shares during the period. Y Intercept Hong Kong Ltd boosted its position in Castle Biosciences by 3.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,206 shares of the company’s stock valued at $690,000 after buying an additional 845 shares during the last quarter. Truist Financial Corp grew its position in shares of Castle Biosciences by 4.6% during the fourth quarter. Truist Financial Corp now owns 21,303 shares of the company’s stock worth $568,000 after buying an additional 928 shares in the last quarter. Finally, Bailard Inc. raised its stake in Castle Biosciences by 12.5% during the fourth quarter. Bailard Inc. now owns 9,900 shares of the company’s stock valued at $264,000 after buying an additional 1,100 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Castle Biosciences news, insider Derek J. Maetzold sold 2,130 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $19.52, for a total transaction of $41,577.60. Following the completion of the transaction, the insider now owns 78,335 shares in the company, valued at approximately $1,529,099.20. This trade represents a 2.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The disclosure for this sale can be found here. In the last three months, insiders sold 44,204 shares of company stock worth $1,055,988. 7.20% of the stock is currently owned by company insiders.

Castle Biosciences Price Performance

NASDAQ:CSTL opened at $20.98 on Tuesday. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The firm has a market capitalization of $587.59 million, a price-to-earnings ratio of 104.91 and a beta of 0.98. The stock’s 50 day moving average price is $24.59 and its two-hundred day moving average price is $28.25. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on CSTL shares. Stephens restated an “overweight” rating and issued a $41.00 target price on shares of Castle Biosciences in a research report on Thursday, January 2nd. Robert W. Baird increased their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Castle Biosciences currently has an average rating of “Buy” and a consensus target price of $40.00.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.